Pfizer documents: Cumulative Analysis of Post-authorization Adverse Event Reports

Released April 1, 2022

Although the report contains a list of adverse events spanning 9 pages (Appendix 1), Pfizer still concludes that these findings of their “signal detection analyses are consistent with the known safety profile” of their product BNT162b2 and the “cumulative post-marketing experience confirms a favourable benefit-risk balance”.

Latest articles

Non-GMO Project Is it possible to create a non-GMO product using genetic...
Carlos A. Monteiro Orthodox teaching and practice on nutrition and health almost...
What They Don’t Want to Tell You About Genetically Modified Crops and...
Environmental Health Symposium While we were distracted with Covid-19, lockdowns, mask mandates,...
Royal Lee “There is only one test for safety and wholesomeness in...
Weston A. Price Foundation WE HAVE ALWAYS PROCESSED OUR FOOD; this is...

Thank you!

The form has been submitted successfully!